LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-raf-ERK1/2-mTOR pathway in breast cancer patients

PLoS Genetics

Volumn 8, Issue 3, 2012, Pages

  Duong, MyLinh T ^a,b   Akli, Said ^a   Wei, Caimiao ^a   Wingate, Hannah F ^a   Liu, Wenbin ^a   Lu, Yiling ^a   Yi, Min ^a   Mills, Gordon B ^a,b   Hunt, Kelly K ^a   Keyomarsi, Khandan ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BIM PROTEIN; CYCLIN DEPENDENT KINASE 2; CYCLIN E; KI 67 ANTIGEN; LOW MOLECULAR WEIGHT CYCLIN E; MAMMALIAN TARGET OF RAPAMYCIN; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RAPAMYCIN; ROSCOVITINE; SORAFENIB; UNCLASSIFIED DRUG; BENZENESULFONIC ACID DERIVATIVE; BRAF PROTEIN, HUMAN; CDK2 PROTEIN, HUMAN; ISOPROTEIN; MTOR PROTEIN, HUMAN; PURINE DERIVATIVE; PYRIDINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CARCINOGENICITY; CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL MATURATION; CELL PROTECTION; CELL STRUCTURE; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MICROARRAY; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; ACINAR CELL; ANIMAL; BREAST TUMOR; CANCER INVASION; CELL PROLIFERATION; CELL TRANSFORMATION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; NUDE MOUSE; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR CELL LINE; UDDER;

MUS MUSCULUS;

ACINAR CELLS; ANIMALS; BENZENESULFONATES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MAMMARY GLANDS, ANIMAL; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; PROGNOSIS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS B-RAF; PURINES; PYRIDINES; RETROSPECTIVE STUDIES; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84859248509     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1002538     Document Type: Article

References (58)

1. Bortner DM, Rosenberg MP, (1997) Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 17: 453-459.
2. Keyomarsi K, Herliczek TW, (1997) The role of cyclin E in cell proliferation, development and cancer. Prog Cell Cycle Res 3: 171-191.
3. Bito T, Ueda M, Ito A, Ichihashi M, (1997) Less expression of cyclin E in cutaneous squamous cell carcinomas than in benign and premalignant keratinocytic lesions. J Cutan Pathol 24: 305-308.
4. Keyomarsi K, Conte D Jr, Toyofuku W, Fox MP, (1995) Deregulation of cyclin E in breast cancer. Oncogene 11: 941-950.
5. Dutta A, Chandra R, Leiter LM, Lester S, (1995) Cyclins as markers of tumor proliferation: immunocytochemical studies in breast cancer. Proc Natl Acad Sci U S A 92: 5386-5390.
6. Erlanson M, Portin C, Linderholm B, Lindh J, Roos G, et al. (1998) Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood 92: 770-777.
7. Sakaguchi T, Watanabe A, Sawada H, Yamada Y, Yamashita J, et al. (1998) Prognostic value of cyclin E and p53 expression in gastric carcinoma. Cancer 82: 1238-1243.
8. Koff A, Giordano A, Desai D, Yamashita K, Harper JW, et al. (1992) Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 257: 1689-1694.
9. Draetta GF, (1994) Mammalian G1 cyclins. Curr Opin Cell Biol 6: 842-846.
10. Bresnahan WA, Boldogh I, Ma T, Albrecht T, Thompson EA, (1996) Cyclin E/Cdk2 activity is controlled by different mechanisms in the G0 and G1 phases of the cell cycle. Cell Growth Differ 7: 1283-1290.
11. Keyomarsi K, Pardee AB, (1993) Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A 90: 1112-1116.
12. Harwell RM, Porter DC, Danes C, Keyomarsi K, (2000) Processing of cyclin E differs between normal and tumor breast cells. Cancer Res 60: 481-489.
13. Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, et al. (2001) Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 21: 6254-6269.
14. Porter DC, Keyomarsi K, (2000) Novel splice variants of cyclin E with altered substrate specificity. Nucleic Acids Res 28: E101.
15. Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, et al. (2005) The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem 280: 15148-15157.
16. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, et al. (2002) Cyclin E and survival in patients with breast cancer. N Engl J Med 347: 1566-1575.
17. Weaver VM, Lelievre S, Lakins JN, Chrenek MA, Jones JC, et al. (2002) beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2: 205-216.
18. Gudjonsson T, Ronnov-Jessen L, Villadsen R, Rank F, Bissell MJ, et al. (2002) Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. J Cell Sci 115: 39-50.
19. Petersen OW, Ronnov-Jessen L, Howlett AR, Bissell MJ, (1992) Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci U S A 89: 9064-9068.
20. Barcellos-Hoff MH, Aggeler J, Ram TG, Bissell MJ, (1989) Functional differentiation and alveolar morphogenesis of primary mammary cultures on reconstituted basement membrane. Development 105: 223-235.
21. Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge JS, (2001) ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 3: 785-792.
22. Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ, (2010) HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 122: 35-43.
23. Fata JE, Mori H, Ewald AJ, Zhang H, Yao E, et al. (2007) The MAPK(ERK-1,2) pathway integrates distinct and antagonistic signals from TGFalpha and FGF7 in morphogenesis of mouse mammary epithelium. Dev Biol 306: 193-207.
24. Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, et al. (2006) Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 66: 1526-1535.
25. Wingate H, Puskas A, Duong M, Bui T, Richardson D, et al. (2009) Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle 8: 1062-1068.
26. Yokota T, Bui T, Liu Y, Yi M, Hunt KK, et al. (2007) Differential regulation of elafin in normal and tumor-derived mammary epithelial cells is mediated by CCAAT/enhancer binding protein beta. Cancer Res 67: 11272-11283.
27. Nanos-Webb A, Jabbour NA, Multani AS, Wingate H, Oumata N, et al. (2011) Targeting low molecular weight cyclin E (LMW-E) in breast cancer. Breast cancer research and treatment.
28. Akli S, Van Pelt CS, Bui T, Meijer L, Keyomarsi K, (2011) Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. Cancer Res 71: 3377-3386.
29. Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM, (1996) Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 10: 1979-1990.
30. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, et al. (2002) The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 111: 29-40.
31. Reginato MJ, Mills KR, Becker EB, Lynch DK, Bonni A, et al. (2005) Bim regulation of lumen formation in cultured mammary epithelial acini is targeted by oncogenes. Mol Cell Biol 25: 4591-4601.
32. Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, et al. (2007) Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 67: 7212-7222.
33. Liotta LA, (1986) Tumor invasion and metastases-role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res 46: 1-7.
34. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, et al. (2006) Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 5: 2512-2521.
35. Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, et al. (2009) Functional proteomic profiling of AML predicts response and survival. Blood 113: 154-164.
36. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, et al. (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69: 4116-4124.
37. Bagheri-Yarmand R, Biernacka A, Hunt KK, Keyomarsi K, (2010) Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. Cancer Res 70: 5074-5084.
38. Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, et al. (2004) Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 64: 3198-3208.
39. Mueller MM, Peter W, Mappes M, Huelsen A, Steinbauer H, et al. (2001) Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Am J Pathol 159: 1567-1579.
40. Pajalunga D, Crescenzi M, (2004) Regulation of cyclin E protein levels through E2F-mediated inhibition of degradation. Cell Cycle 3: 1572-1578.
41. Geng Y, Eaton EN, Picon M, Roberts JM, Lundberg AS, et al. (1996) Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene 12: 1173-1180.
42. Akli S, Bui T, Wingate H, Biernacka A, Moulder S, et al. (2010) Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clin Cancer Res 16: 1179-1190.
43. Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, et al. (2010) A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene 29: 3896-3907.
44. Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, et al. (2008) Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res 68: 7966-7974.
45. MacCallum DE, Melville J, Frame S, Watt K, Anderson S, et al. (2005) Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 65: 5399-5407.
46. Foell JL, Max D, Giersberg C, Korholz D, Staege MS, (2008) Sensitivity of Hodgkin's lymphoma cell lines to the cell cycle inhibitor roscovitine. Anticancer Res 28: 887-894.
47. Pampaloni F, Reynaud EG, Stelzer EH, (2007) The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 8: 839-845.
48. Fournier MV, Martin KJ, Kenny PA, Xhaja K, Bosch I, et al. (2006) Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. Cancer Res 66: 7095-7102.
49. Martin KJ, Patrick DR, Bissell MJ, Fournier MV, (2008) Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS One 3: e2994.
50. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, et al. (2004) JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18: 189-218.
51. Hoyle PE, Moye PW, Steelman LS, Blalock WL, Franklin RA, et al. (2000) Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. Leukemia 14: 642-656.
52. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, et al. (1997) Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 17: 5598-5611.
53. Band V, Sager R, (1989) Distinctive traits of normal and tumor-derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types. Proc Natl Acad Sci U S A 86: 1249-1253.
54. Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, DeCaprio JA, et al. (1996) Cyclin E, a redundant cyclin in breast cancer. Proc Natl Acad Sci U S A 93: 15215-15220.
55. Moody SE, Sarkisian CJ, Hahn KT, Gunther EJ, Pickup S, et al. (2002) Conditional activation of Neu in the mammary epitheilium of transgenic mice results in reersible pulmonary metastasis. Cancer Cell 2: 451-461.
56. Debnath J, Muthuswamy SK, Brugge JS, (2003) Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30: 256-268.
57. Kaplan E, Meier P, (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481.
58. Cox D, (1972) Regression models and life-tables (with discussion). J R Stat Soc Series B 34: 187-220.